Chicago-based Xentria advances Illinois’ position in life sciences innovation through strategic academic partnership*
Illinois’ biotechnology sector continues to demonstrate its growing prominence with Xentria, Inc., a Chicago-based clinical-stage biotherapeutics company, announcing an exclusive worldwide licensing agreement with New York University (NYU) to advance a potential disease-modifying cardiovascular therapy.
This strategic partnership underscores the innovative spirit driving Illinois’ life sciences ecosystem, combining NYU Langone Health’s distinguished biomedical research capabilities with Xentria’s drug development expertise. The collaboration focuses on advancing GL-12, a promising therapeutic formulation that could transform cardiovascular treatment approaches.
“This partnership exemplifies the caliber of innovation emerging from Illinois’ biotechnology community,” said John Conrad, President and CEO of iBIO. “Xentria’s success in securing this agreement demonstrates how our member companies are actively shaping the future of healthcare through strategic collaborations and breakthrough research.”
Under the leadership of President Tom Shea, Xentria will spearhead the clinical development and commercialization of GL-12, acting as the clinical sponsor for Investigational New Drug applications. “Our commitment to advancing this drug’s development is driven by our enthusiasm for collaborating with pioneering researchers like Dr. David Park of NYU Langone Health, to help translate their groundbreaking discoveries from the lab to clinical practice,” said Shea.
Founded in 2020, Xentria represents a new generation of Illinois biotech companies that are advancing challenging drug development through innovative partnerships. Their mission aligns perfectly with Illinois’ growing reputation as a hub for life sciences innovation, combining ambitious drug development goals with meaningful patient engagement.
This agreement marks another significant milestone in Illinois’ expanding life sciences sector, showcasing our state’s ability to foster companies that are at the forefront of therapeutic innovation. As our member companies continue to forge meaningful partnerships and advance groundbreaking research, Illinois strengthens its position as a leading destination for biotechnology development.
iBIO congratulates Xentria on this achievement and looks forward to supporting their continued growth and success within our vibrant life sciences community.